Optimising the use of β-blockers in older patients with heart failure

Drugs and Aging

Volumn 19, Issue 9, 2002, Pages 671-684

  Owen, Andrew ^a  

^a KENT AND CANTERBURY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; BUCINDOLOL; CARVEDILOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; LOSARTAN; METOPROLOL; SPIRONOLACTONE; VALSARTAN;

ADULT; AGED; BRADYCARDIA; CLINICAL TRIAL; DOSE RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; ELDERLY CARE; HEART FAILURE; HUMAN; HYPOTENSION; MORTALITY; OUTPATIENT; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SURVIVAL; TITRIMETRY; VERTIGO;

EID: 0036032396     PISSN: 1170229X     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002512-200219090-00004     Document Type: Review

References (40)

1. Purcell IF, Poole-Wilson PA. Heart failure: Why and how to define it? Eur J Heart Fail 1999; 1: 7-10
2. Remme WJ, Swedberg K, editors. Task force for the diagnosis and treatment of chronic heart failure. European Society of Cardiology: Guidelines for the diagnosis and treatment of chronic heart failure. Eur Heart J 2001: 22: 1527-60
3. Wong WF, Gold S, Fukuyama O, et al. Diastolic dysfunction in elderly patients with congestive heart failure. Am J Cardiol 1989; 63: 1526-8
4. Cowie MR, Struthers AD, Wood DA, et al. Value of natriuretic peptide peptides in assessment of patients with possible new heart failure in primary care. Lancet 1997; 350: 1349-53
5. Owen A, Cox S. Diagnosis of heart failure in elderly patients in primary care. Eur J Heart Fail 2001; 3: 79-81
6. Erhardt AR, Cline CMJ. Organisation of the care of patients with heart failure. Lancet 1998; 352: (S/1) 15-8
7. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure: Results of the cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987; 316: 1429-35
8. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators. N Engl J Med 1991; 325: 293-302
9. Clark KW, Gray D, Hampton JR. Evidence of inadequate investigation and treatment of patients with heart failure. Br Heart J 1994; 871: 584-7
10. Packer M, Poole-Wilson PA, Armstrong PW, et al. On behalf of the ATLAS Study Group. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. Circulation 1999; 100: 2312-8
11. Gavazzi A, Marioni R, Campana C, Quinapril/Captopril Congestive Heart Failure Study Group, et al. Comparative trial of quinapril versus captopril in mild to moderate congestive heart failure. J Hypertens Suppl 1994; 12 (4): S89-93
12. Acanfora D, Furgi G, Trojano L, et al. Quinapril in patients with congestive heart failure: Controlled trial versus captopril. Am J Ther 1997; 4 (5-6): 181-8
13. Lechat P, Garnham SP, Desche P, et al. Efficacy and acceptability of perindopril in mild to moderate chronic congestive heart failure. Am Heart J 1993; 126 (3 Pt 2): 798-806
14. Bounhoure JP, Bottineau G, Lechat P, et al. Value of perindopril in the treatment of chronic congestive heart failure. Multicenter double-blind placebo-controlled study. Clin Exp Hypertens A 1989; 11 Suppl. 2: 575-86
15. Thomas JA, Marks BH. Plasma norepinephrine in congestive heart failure. Am J Cardiol 1978; 41: 233-43
16. Cohn JN, Levine TB, Olivari MT, et al. Plasma norepinephrine as a guide to prognosis in patients with congestive heart failure. N Engl J Med 1984; 311: 819-23
17. White M, Wiechmann RJ, Roden RL, et al, Cardiac Β-adrenergic neuroeffector systems in acute myocardial dysfunction related to brain injury: Evidence for catecholamine mediated myocardial damage. Circulation 1995; 92: 2183-9
18. Waagstein F, Hjalmarson A, Wallentin I. Effect of chronic beta-adrenergic receptor blockade in congestive cardiomyopathy. Br Heart J 1975; 37: 1022-36
19. Swedberg K, Hjalmarson A, Waagstein F, et al. Prolongation of survival in congestive cardiomyopathy by beta-receptor blockade. Lancet 1979; 1: 1374-6
20. Epstein SE, Braunwald E. The effect of beta-adrenergic blockade on patterns of urinary sodium excretion: Studies in normal subjects and in patients with heart disease. Ann Intern Med 1966; 65: 20-7
21. Packer M, Bristow MR, Cohn JN, et al. The effects ofcarvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 1996; 334: 1349-55
22. CIBIS-II Investigators and Committee. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): A randomised trial. Lancet 1999; 353: 9-13
23. MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: metoprolol CR/XL randomised intervention trial in congestive heart failure (MERIT-HF). Lancet 1999; 353: 2001-7
24. Packer M, Coats AJS, Fowler MB, et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 2001; 344: 1651-8
25. The Beta-blocker Evaluation of Survival Trial Investigators. A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. N Engl J Med 2001; 344: 1659-67
26. Goldstein S, Fagerberg B, Hjalmarson A, et al. Metoprolol controlled release/extended release in patients with severe heart failure: Analysis of the experience in the MERIT-HF Study. J Am Coll Cardiol 2001; 38: 932-8
27. Pfeffer MA, Stevenson LW. β-Adrenergic blockers and survival in heart failure. N Engl J Med 1996; 334: 1396-7
28. Yancy CW, Fowler MB, Colucci WS, et al. Race and the response to adrenergic blockade with carvedilol in patients with chronic heart failure. N Engl J Med 2001; 344: 1358-65
29. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on the morbidity and mortality in patients with severe heart failure: Randomised Aldactone Evaluation Study Investigators. N Engl J Med 1999; 341: 709-17
30. Pitt B, Poole-Wilson PA, Segal R, et al. Effect of losartan compared to captopril on mortality in patients with symptomatic heart failure: Randomised trial, the Losartan Heart Failure Survival Study ELITE II. Lancet 2000; 353: 1582-7
31. Cohn JN, Tognoni G, for the Valsartan Heart Failure Trial Investigators. A randomised trial of the angiotensin receptor blocker valsartan in chronic heart failure. N Engl J Med 2001; 345: 1667-75
32. Owen A. Experience of commencing carvedilol in elderly patients with heart failure in a routine out patient clinic. Eur J Heart Fail 2000; 2: 287-9
33. Bristow MR, Gilbert EM, Abraham WT, et al. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. Circulation 1996; 94: 2807-16
34. Yusuf S, Zucker D, Preduzzi P, et al. Effect of coronary artery bypass graft surgery on survival: Overview of 10 year results from randomised trials by the Coronary Artery Bypass Graft Surgery Trialists Collaboration. Lancet 1994; 344: 563-70
35. Tan LB, Murphy R. Shifts in mortality curves: saving or extending lives? Lancet 1999; 354: 1378-81
36. Owen A, Croucher L. Effect of an exercise programme for elderly patients with heart failure. Eur J Heart Fail 2000; 2: 65-70
37. Packer MP, Colucci WS, Sackner-Bemstein JD, et al. for the PRECISE Study Group. Double-blind, placebo-controlled study of the effects of carvedilol in patients with moderate to severe heart failure. The PRECISE Trial. Circulation 1996; 94: 2793-9
38. Rochon PA, Tu JV, Anderson GM, et al. Rate of heart failure and 1 year survival for older people receiving low dose Β-blocker therapy after myocardial infarction. Lancet 2000; 356: 639-44
39. Drazner MH, Rame JE, Stevenson LW, et al. Prognostic importance of elevated jugular venous pressure and a third heart sound in patients with heart failure. N Engl J Med 2001; 345: 574-81
40. Blue L, Lang E, McMurray JJV, et al. Randomised controlled trial of specialist nurse intervention in heart failure. BMJ 2001; 323: 715-8